Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.EIGR · Entity 16554 | Director | April 12, 2017 | April 14, 2017 |
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | Director | June 08, 2026 | June 11, 2026 |
| Ocera Therapeutics, Inc.OCRX · Entity 171193 | Director | December 11, 2017 | December 11, 2017 |
| Panacea Acquisition Corp. IIPANA · Entity 114006 | Director | April 06, 2021 | April 07, 2021 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director | February 05, 2025 | February 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eiger BioPharmaceuticals, Inc.
Report date April 12, 2017 · Filed April 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.50 · Expires 2027-04-12 | Direct | 10,000 |
Reported balance
After 2017-04-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-12 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests in equal monthly installments over 12 months measured from April 12, 2017 subject to Reporting Person's continuous service status as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over 12 months measured from April 12, 2017 subject to Reporting Person's continuous service status as of each such date.
Eloxx Pharmaceuticals, Inc.
Report date June 08, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2036-06-08 | Direct | 13,587 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 13,587 · Balance 13,587 F1: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
Ocera Therapeutics, Inc.
Report date December 11, 2017 · Filed December 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 1
1 source rowRow 1 · 2017-12-11 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. F3: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.85 · Expires 2023-12-19 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-12-11 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2024-06-11 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-12-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F7: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merger for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-12-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F8: This Out of the Money Option, became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.26 · Expires 2026-06-13 | Direct | 0 |
Reported balance
After 2017-12-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-12-11 · Disposition to issuer · Disposed 12,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F9: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.
F3: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes.
F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR.
F5: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore.
F6: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration.
F7: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merger for no consideration.
F8: This Out of the Money Option, became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.
F9: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.
Panacea Acquisition Corp. II
Report date April 06, 2021 · Filed April 07, 2021
This filing explicitly reported no securities owned.
Tyra Biosciences, Inc.
Report date February 05, 2025 · Filed February 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Canaan XI L.P | 3,700,705 |
Reported balance
After 2025-02-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-02-05 · Sale · Disposed 1,890 · Balance 3,700,705 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy 2020+ Co-Investment L.P. - Series 7 | 443,885 |
Reported balance
After 2025-02-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-05 · Sale · Disposed 3,511 · Balance 443,885 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 ("Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.
F3: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 ("Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 11, 2026 00:00 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 13,587 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266276 · ownership.xml · derivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,587 Underlying: Common Stock · 13,587 shares Expires 2036-06-08 F1 · derivative.exercise_date: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:43 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,511 | $13.76 | $48,315.22 |
DisclosureSEC source: 0000950170-25-016385 · ownership.xml · nonDerivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 443,885 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 ("Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:43 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,890 | $13.76 | $26,008.48 |
DisclosureSEC source: 0000950170-25-016385 · ownership.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P Disclosed balance after: 3,700,705 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 22:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 4,825 | $16.26 | $78,466.08 |
DisclosureSEC source: 0000950170-25-009278 · ownership.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P Disclosed balance after: 3,702,595 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 21, 2025 Filed Jan 21, 2025 22:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,993 | $16.36 | $65,335.86 |
DisclosureSEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 5 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P Disclosed balance after: 3,707,420 F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.58. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 17, 2025 Filed Jan 21, 2025 22:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 461 | $16.40 | $7,560.45 |
DisclosureSEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 4 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 447,396 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 17, 2025 Filed Jan 21, 2025 22:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 12,808 | $16.40 | $210,052.48 |
DisclosureSEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 3 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,711,413 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 22:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 835 | $16.29 | $13,599.65 |
DisclosureSEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 447,857 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 22:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 6,944 | $16.29 | $113,096.93 |
DisclosureSEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,724,221 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 566 | $16.84 | $9,530.65 |
DisclosureSEC source: 0000950170-24-131084 · ownership.xml · nonDerivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 448,692 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:47 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 4,706 | $16.84 | $79,242.45 |
DisclosureSEC source: 0000950170-24-131084 · ownership.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,731,165 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:43 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,371 | $17.32 | $41,061.22 |
DisclosureSEC source: 0000950170-24-124184 · ownership.xml · nonDerivative · entry 4 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 449,258 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:43 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 19,720 | $17.32 | $341,512.93 |
DisclosureSEC source: 0000950170-24-124184 · ownership.xml · nonDerivative · entry 3 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,735,871 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:43 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 5,635 | $17.18 | $96,783.94 |
DisclosureSEC source: 0000950170-24-124184 · ownership.xml · nonDerivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 451,629 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:43 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 46,856 | $17.18 | $804,775.23 |
DisclosureSEC source: 0000950170-24-124184 · ownership.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,755,591 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 00:24 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,126 | $16.77 | $18,881.11 |
DisclosureSEC source: 0000950170-24-122639 · ownership.xml · nonDerivative · entry 4 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 457,264 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 00:24 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 9,367 | $16.77 | $157,068.67 |
DisclosureSEC source: 0000950170-24-122639 · ownership.xml · nonDerivative · entry 3 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,802,447 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 04, 2024 Filed Nov 7, 2024 00:24 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 116 | $17.01 | $1,972.70 |
DisclosureSEC source: 0000950170-24-122639 · ownership.xml · nonDerivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 458,390 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 04, 2024 Filed Nov 7, 2024 00:24 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 960 | $17.01 | $16,325.76 |
DisclosureSEC source: 0000950170-24-122639 · ownership.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,811,814 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 22:18 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 73 | $17.16 | $1,252.64 |
DisclosureSEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 8 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 458,506 F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 22:18 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,878 | $16.54 | $47,614.78 |
DisclosureSEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 7 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 458,579 F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 22:18 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommmon Stock | 604 | $17.16 | $10,364.28 |
DisclosureSEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 6 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,812,774 F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 22:18 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 23,938 | $16.54 | $396,039.85 |
DisclosureSEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 5 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,813,378 F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 22:18 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 10,750 | $16.46 | $176,940.70 |
DisclosureSEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 4 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 461,457 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 22:18 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 89,390 | $16.46 | $1,471,323.64 |
DisclosureSEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 3 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,837,316 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 22:18 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,189 | $16.17 | $19,224.94 |
DisclosureSEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 472,207 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 22:18 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 9,889 | $16.17 | $159,895.24 |
DisclosureSEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,926,706 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:30 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 18,600 | $0.00 Strike: $15.94 | $0.00 |
DisclosureSEC source: 0000950170-24-067351 · ownership.xml · derivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2034-05-28 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0001209191-23-033774 · doc4.xml · derivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2033-05-30 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:46 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001209191-22-036979 · doc4.xml · derivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2032-06-12 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 13, 2022, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries B Preferred Stock · Derivative | 182,258 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036420 · doc4.xml · derivative · entry 5 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 0 Underlying: Common Stock · 473,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries B Preferred Stock · Derivative | 182,257 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036420 · doc4.xml · derivative · entry 4 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 0 Underlying: Common Stock · 473,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries A Preferred Stock · Derivative | 1,333,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036420 · doc4.xml · derivative · entry 3 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 0 Underlying: Common Stock · 3,463,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 473,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036420 · doc4.xml · nonDerivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 473,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 3,936,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036420 · doc4.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,963,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries B Preferred Stock · Derivative | 182,258 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · derivative · entry 5 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 0 Underlying: Common Stock · 473,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries B Preferred Stock · Derivative | 182,257 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · derivative · entry 4 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 0 Underlying: Common Stock · 473,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries A Preferred Stock · Derivative | 1,333,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · derivative · entry 3 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 0 Underlying: Common Stock · 3,463,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 473,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · nonDerivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7 Disclosed balance after: 473,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 22:36 UTC Amendment | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 3,936,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036637 · doc4a.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Canaan XI L.P. Disclosed balance after: 3,936,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:25 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,500 | Not disclosed Strike: $2.26 | Not disclosed |
DisclosureSEC source: 0000899243-17-028423 · doc4.xml · derivative · entry 5 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2026-06-13 F4 · price: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · price: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F9 · price: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · derivative.exercise_date: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F9 · derivative.exercise_date: This Out of the Money Option, which became fully vested on June 14, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.26, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:25 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $3.76 | Not disclosed |
DisclosureSEC source: 0000899243-17-028423 · doc4.xml · derivative · entry 4 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-17 F4 · price: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · price: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F8 · price: This Out of the Money Option, became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · derivative.exercise_date: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F8 · derivative.exercise_date: This Out of the Money Option, became fully vested on June 18, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $3.76, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:25 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $7.84 | Not disclosed |
DisclosureSEC source: 0000899243-17-028423 · doc4.xml · derivative · entry 3 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-06-11 F4 · price: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · price: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F7 · price: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merger for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · derivative.exercise_date: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F7 · derivative.exercise_date: This Out of the Money Option, which became fully vested on July 11, 2015, was cancelled in connection with the Merger for no consideration. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:25 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $7.85 | Not disclosed |
DisclosureSEC source: 0000899243-17-028423 · doc4.xml · derivative · entry 2 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-12-19 F4 · price: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · price: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6 · price: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · derivative.exercise_date: (Continued from Footnote 4) All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6 · derivative.exercise_date: This Out of the Money Option, which provided for vesting with respect to 25% of such options on December 19, 2014, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 15:25 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | Disposition to issuerCommon Stock | 12,500 | $1.52 | $19,000.00 |
DisclosureSEC source: 0000899243-17-028423 · doc4.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. F3 · price: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 16:40 UTC | Ocera Therapeutics, Inc. OCRX · Entity 171193 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001274644-17-000057 · wf-form4_149816403160205.xml · nonDerivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units shall vest in full on the earlier of the one year anniversary of the grant or the next annual meeting of shareholders; provided, in all cases, that the Reporting Person is, as of each such vesting date, then a director of the Issuer. Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 14:32 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0001209191-17-026970 · doc4.xml · derivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-04-12 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from April 12, 2017 subject to Reporting Person's continuous service status as of each such date. Read SEC document |
| March 28, 2016 Filed Sep 15, 2016 18:46 UTC Amendment | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0001209191-16-141651 · doc4a.xml · derivative · entry 1 Kjellson Nina S · CIK 0001381980 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-03-28 F1 · derivative.exercise_date: The option vests in equal monthly installments over 12 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date. F2 · derivative.exercise_date: The option grant was approved by Issuer's board of directors on March 28, 2016, subject to stockholder approval of an amendment of the Issuer's 2013 Equity Incentive Plan (the "Plan") under which the option was granted. Issuer's stockholders approved the amendment to the Plan on August 29, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.